Safety Study of Abatacept to Treat Rheumatoid Arthritis (B)

Launched by BRISTOL-MYERS SQUIBB · Mar 16, 2010

Keywords

ClinConnect Summary

This clinical trial is studying the safety of a medication called abatacept for treating rheumatoid arthritis. Researchers want to see how often patients develop serious infections, cancers, or experience death when treated with abatacept compared to other common medications for rheumatoid arthritis. The trial is currently active but not recruiting new participants, which means it is ongoing but not looking for more people to join right now.

To be eligible for this study, participants need to be at least 18 years old and have a diagnosis of rheumatoid arthritis. They must also be starting treatment with abatacept or another similar medication. Participants will be asked to sign a consent form and should be able to read and write in English. While there are no specific exclusions for this trial, it’s important for interested patients to understand that they are being monitored closely for any health changes throughout the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Signed informed consent
• • Diagnosis of rheumatoid arthritis
• • \> 18 years at index treatment initiation or switch
• • Starting treatment with abatacept or new disease-modifying anti-rheumatic drug (including switching or adding) or biologic disease modifying drug.
• • Read/write English
• Exclusion Criteria:
• • None